本研究的主要目的是比較 nivolumab 聯合 ipilimumab 對比標準治療（SOC）（sorafenib 或 lenvatinib）於所有未曾接受過全身性治療的晚期肝細胞癌（HCC）隨機參與者中的整體存活期（OS）。
適應症：Hepatocellular Carcinoma
收案條件
納入條件
- Participants must have a diagnosis of HCC based on histological confirmation
- Participants must have an advanced HCC
- Participants must have at least one Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable previously untreated lesion
- Child-Pugh score 5 or 6
- Eastern Cooperative Oncology Group (ECOG) performance status(PS) 0 or 1
排除條件
- Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
- Prior liver transplant
- Episodes of hepatic encephalopathy (greater than or equal to \[\>=\] Grade 2) within 12 months prior to randomization
- Active brain metastases or leptomeningeal metastases
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。